20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Tectonic Therapeutic, Inc. (TECX) operates in the BIOTECHNOLOGY industry and is headquartered in Watertown, United States with about 60 employees. Its market capitalization is roughly $387 million. In the fiscal year ended 2025-12-31, TECX reported $0M in revenue and ($74M) in net income.
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines.
Interactive charts & full statements →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | — | — | — | — | — |
| Gross Profit | — | — | ($2M) | ($1M) | ($4M) | ($1M) | ($1M) | ($1M) | $0M | $0M | — |
| Gross Margin % | — | — | — | — | — | — | — | — | — | — | — |
| Operating Income (EBIT) | ($95M) | ($84M) | ($58M) | ($45M) | ($33M) | ($16M) | ($120M) | ($76M) | ($46M) | ($18M) | ($5M) |
| Operating Margin % | — | — | — | — | — | — | — | — | — | — | — |
| Net Income | ($86M) | ($74M) | ($58M) | ($43M) | ($32M) | ($9M) | ($120M) | ($73M) | ($46M) | ($19M) | ($5M) |
| Net Margin % | — | — | — | — | — | — | — | — | — | — | — |
| EBITDA | ($84M) | ($71M) | ($56M) | ($41M) | ($31M) | ($8M) | ($119M) | ($72M) | ($46M) | ($19M) | ($5M) |
| Earnings Per Share (EPS) | $-4.59 | $-4.05 | $-3.93 | $-11.53 | $-8.83 | $-2.50 | $-39.68 | $-31.92 | $-23.41 | $-9.35 | $-2.34 |
| Shares Outstanding (M) | 19M | 18M | 15M | 4M | 4M | 4M | 3M | 2M | 2M | 2M | 2M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Profit | — | — | — | — | $0M | $0M | ($1M) | $0M |
| Gross Margin % | — | — | — | — | — | — | — | — |
| Operating Income (EBIT) | ($24M) | ($27M) | ($22M) | ($22M) | ($22M) | ($18M) | ($14M) | ($20M) |
| Operating Margin % | — | — | — | — | — | — | — | — |
| Net Income | ($22M) | ($25M) | ($19M) | ($19M) | ($20M) | ($16M) | ($12M) | ($18M) |
| Net Margin % | — | — | — | — | — | — | — | — |
| EBITDA | ($22M) | ($25M) | ($18M) | ($19M) | ($19M) | ($16M) | ($12M) | ($17M) |
| Earnings Per Share (EPS) | $-1.18 | $-1.34 | $-1.05 | $-1.02 | $-1.07 | $-0.93 | $-0.84 | $-1.20 |
| Shares Outstanding (M) | 19M | 19M | 18M | 19M | 19M | 17M | 15M | 15M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($72M) | ($60M) | ($59M) | ($41M) | ($97M) | ($12M) | ($99M) | ($68M) | ($38M) | ($16M) | ($3M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $0M | $2M | $1M | $2M | $2M | $0M | $0M |
| Free Cash Flow (FCF) | ($72M) | ($60M) | ($59M) | ($41M) | ($97M) | ($15M) | ($100M) | ($69M) | ($39M) | ($17M) | ($3M) |
| FCF Margin % | — | — | — | — | — | — | — | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($21M) | ($18M) | ($14M) | ($18M) | ($15M) | ($13M) | ($17M) | ($20M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($22M) | ($18M) | ($14M) | ($18M) | ($15M) | ($13M) | ($17M) | ($20M) |
| FCF Margin % | — | — | — | — | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $237M | $261M | $153M | $39M | $47M | $33M | $271M | $201M | $133M | $7M | $5M |
| Cash & Cash Equivalents | $227M | $254M | $141M | $29M | $36M | $28M | $260M | $187M | $126M | $6M | $5M |
| Total Liabilities | $13M | $10M | $12M | $124M | $93M | $48M | $17M | $15M | $11M | $4M | $1M |
| Total Debt (Short + Long-Term) | $2M | $1M | $3M | $2M | $1M | $0M | $0M | $0M | $0M | $0M | $0M |
| Total Shareholders' Equity | $224M | $251M | $141M | ($85M) | ($46M) | ($15M) | $254M | $186M | $122M | $3M | $4M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive TECX viewer.
About TickerBase · Data methodology & sources · Privacy · Terms